Appeal No. 2006-2466 Page 3
Application No. 09/835,759
inhibiting the proliferation of B cells; inhibiting the differentiation of B cells to plasma
cells; causing a B cell dysfunction which results in an immunotherapeutic benefit;
inhibiting secretion of cytokines or other tumor-promoting soluble factor(s) by activated
B cells; [and] reduction in the number of B cells. . . .” Id., page 8. As an example, the
specification states that “anti-CD22 mAb [monoclonal antibody] . . . may selectively bind
to mature and/or memory B cells . . . and facilitate or result in B cell depletion.” Id.,
page 9. The specification also states that the affinity ligand may be coupled to an anti-B
cell agent, such as ricin A chain. Id., pages 9-10.
Discussion
1. Claim construction
Claims 1-5, 7-12, 69-73, 77, 78, 80-86, 90, 92-96, 100, 102-108, 112, 114, and
115 are pending and on appeal. Appellant has not separately argued any of the claims.
Therefore, the claims stand or fall together. We will focus on claims 1 and 69, which are
representative and read as follows:
1. A composition for treating a TH2 response and for inducing a cell
mediated immune response comprising a TH1 response in an individual
having a TH2/TH1 imbalance associated with a pro-tumor immune
response, the composition comprising: an immunotherapeutic composition
for effecting B cell depletion; and tumor-associated antigen capable of
inducing a cell mediated immune response comprising a TH1 response.
69. A composition comprising:
(a) an immunotherapeutic composition comprising a monoclonal
antibody having binding specificity for CD22 for effecting B cell depletion;
and
(b) tumor-associated antigen capable of inducing a cell mediated
immune response comprising a TH1 response;
wherein the composition is in an amount effective for suppressing a
TH2 response, and for inducing a cell mediated immune response
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007